Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

122.25
+1.200.99%
Post-market: 122.250.00000.00%19:58 EDT
Volume:656.44K
Turnover:80.15M
Market Cap:13.22B
PE:269.48
High:123.44
Open:121.48
Low:120.56
Close:121.05
52wk High:123.44
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.88
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:18.72
PE(LYR):149.09

Loading ...

Corcept Therapeutics rises 28.6%

TIPRANKS
·
Mar 26

What's Behind The Jump In Corcept Therapeutics Stock?

Benzinga
·
Mar 26

US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer

Reuters
·
Mar 25

Corcept Therapeutics Shares up 46.7% After FDA Approves Co's Drug to Treat Ovarian Cancer

THOMSON REUTERS
·
Mar 25

BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer

Reuters
·
Mar 25

FDA Approves Relacorilant With Nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

THOMSON REUTERS
·
Mar 25

FDA approves Corcept Therapeutics’ Lifyorli for certain cancers

TIPRANKS
·
Mar 25

Corcept Therapeutics jump 10% after FDA approves Lifyorli cancer treatment

TIPRANKS
·
Mar 25

Corcept Therapeutics trading halted, volatility trading pause

TIPRANKS
·
Mar 25

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM

Reuters
·
Mar 25

Corcept Chief Development Officer William Guyer disposes of USD 423,000 in common shares

Reuters
·
Mar 25

A Look At Corcept Therapeutics (CORT) Valuation As Shares Trade Below Popular Fair Value Estimates

Simply Wall St.
·
Mar 24

Analysts’ Opinions Are Mixed on These NA Stocks: Corcept Therapeutics (CORT) and Fiserv (FISV)

TIPRANKS
·
Mar 23

Corcept Therapeutics Director G. Leonard Baker Jr acquires USD 3.31 million in common shares

Reuters
·
Mar 20

Corcept faces class action over relacorilant NDA claims after 50.4% stock drop

Reuters
·
Mar 19

Class action lawsuit targets Corcept Therapeutics over alleged securities law violations

Reuters
·
Mar 18

Wolf Haldenstein files securities class action against Corcept Therapeutics over relacorilant statements

Reuters
·
Mar 16

Corcept Therapeutics (CORT) Is Down 5.1% After FDA Relacorilant Rejection And Investor Lawsuits - What's Changed

Simply Wall St.
·
Mar 15

Corcept Chief Development Officer William Guyer Disposes of Common Shares

Reuters
·
Mar 07

Corcept Investors Face April 21 Lead Plaintiff Deadline in Securities Fraud Class Action

Reuters
·
Mar 06